Raymond Woo Sells 4,887 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 4,887 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $24.33, for a total value of $118,900.71. Following the completion of the transaction, the chief technology officer directly owned 203,118 shares of the company’s stock, valued at approximately $4,941,860.94. This trade represents a 2.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Raymond Woo also recently made the following trade(s):

• On Friday, August 21st, Raymond Woo sold 1,979 shares of CeriBell stock. The stock was sold at an average price of $24.02, for a total value of $47,535.58.

CeriBell Stock Up 0.9%

Shares of CBLL opened at $23.63 on Friday. The business’s 50 day moving average is $21.11 and its 200 day moving average is $19.64. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. CeriBell, Inc. has a 12-month low of $10.85 and a 12-month high of $25.33. The company has a market capitalization of $906.92 million, a PE ratio of -13.43 and a beta of 0.95.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The business had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. Research analysts expect that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CeriBell

Several large investors have recently bought and sold shares of CBLL. Strs Ohio purchased a new stake in CeriBell during the first quarter valued at $27,000. Caitong International Asset Management Co. Ltd grew its stake in shares of CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after buying an additional 1,231 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of CeriBell in the 3rd quarter worth about $33,000. Tower Research Capital LLC TRC raised its position in shares of CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after buying an additional 1,801 shares in the last quarter. Finally, Legal & General Group Plc purchased a new stake in shares of CeriBell during the 2nd quarter valued at about $53,000.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Weiss Ratings cut shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 28th. Canaccord Genuity Group boosted their price target on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Barclays raised shares of CeriBell to a “neutral” rating in a report on Tuesday, August 18th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $29.00 target price on shares of CeriBell in a report on Thursday, September 3rd. Finally, BTIG Research reiterated a “buy” rating and issued a $30.00 target price on shares of CeriBell in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, CeriBell presently has an average rating of “Moderate Buy” and a consensus target price of $24.40.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.